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Mutations in SPG11 cause a complicated autosomal recessive form of hereditary spastic
paraplegia (HSP). Mechanistically, there are indications for the dysregulation of the
GSK3β/βCat signaling pathway in SPG11. In this study, we tested the therapeutic
potential of the GSK3β inhibitor, tideglusib, to rescue neurodegeneration associated
characteristics in an induced pluripotent stem cells (iPSCs) derived neuronal model from
SPG11 patients and matched healthy controls as well as a CRISPR-Cas9 mediated
SPG11 knock-out line and respective control. SPG11-iPSC derived cortical neurons,
as well as the genome edited neurons exhibited shorter and less complex neurites
than controls. Administration of tideglusib to these lines led to the rescue of neuritic
impairments. Moreover, the treatment restored increased cell death and ameliorated
the membranous inclusions in iPSC derived SPG11 neurons. Our results provide a first
evidence for the rescue of neurite pathology in SPG11-HSP by tideglusib. The current
lack of disease-modifying treatments for SPG11 and related types of complicated HSP
renders tideglusib a candidate compound for future clinical application.
Keywords: induced pluripotent stem cell, neuronal culture, SPG11, tideglusib, GSK3β inhibitor, hereditary spastic
paraplegia, CRISPR knock-out
INTRODUCTION
Hereditary spastic paraplegias (HSPs) are a heterogeneous group of motor neuron disorders.
Clinically, HSP manifests with progressive lower limb spasticity and weakness due to axonopathy
of corticospinal motor neurons and ascending dorsal columns. Up to date, more than 70 distinct
genetic loci (Spastic Paraplegia Gene SPG1-SPG79) and mutations in more than 50 genes have
been identified in HSP patients (Lo Giudice et al., 2014; Novarino et al., 2014). HSPs can be
inherited in an autosomal dominant, autosomal recessive (AR), and, rarely, in an X-linked manner.
Mutations in SPG11 are the most common genetic cause of AR complicated HSP. Apart from
spastic paraparesis, SPG11 patients present with additional phenotypes that in the majority of
cases include cognitive impairment, thin corpus callosum (TCC), neuropathy, and amyotrophy
(Lo Giudice et al., 2014). Interestingly, mutations in SPG11 encoding spatacsin, were also found in
other motor neuron diseases such as AR juvenile-onset amyotrophic lateral sclerosis (ALS5) and
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AR Charcot-Marie-Tooth disease (Montecchiani et al., 2016;
Orlacchio et al., 2016). This indicates an important function of
SPG11 in a variety of neuronal subtypes and shows that spatacsin
causes multi system neurodegeneration.
Until now, more than 100 mutations in the 40-exon long
SPG11 have been described. The majority of mutations result
in premature stop codons, causing nonsense mediated RNA
decay and/or truncated proteins. This implies a loss of function
mechanism (Stevanin et al., 2013). SPG11 encodes spatacsin (a
2443 aa protein; ∼280 kDa), a potential transmembrane protein
(Paisan-Ruiz et al., 2008) that has been implicated in axonal
maintenance (Pérez-Brangulí et al., 2014). A number of studies
have shown that the protein is linked to the autophagic-lysosomal
machinery (Chang et al., 2014; Renvoise et al., 2014; Varga
et al., 2015; Branchu et al., 2017). In addition, siRNA mediated
knock-down of SPG11, led to reduced neurite complexity of
mouse dissociated cortical neurons (Pérez-Brangulí et al., 2014).
Moreover, membrane-bound structures were observed within
the processes of SPG11 patient, induced pluripotent stem cells
(iPSC) derived cortical neurons (Pérez-Brangulí et al., 2014).
This observation has been related to alterations in the transport
of organelles, specifically anterograde transport and a lack of
synaptic vesicle movement in SPG11 neurons (Pérez-Brangulí
et al., 2014). Additionally iPSC-derived neural progenitor cells
(NPCs) described a prominent neurodevelopmental defect.
Reduced NPC proliferation was mediated by increased GSK3β
activity followed by impairment of β-catenin signaling pathway
(Mishra et al., 2016). Interestingly, administration of the
specific GSK3β inhibitor tideglusib rescued the observed NPC
proliferation defect (Mishra et al., 2016).
In the present study, we asked, whether tideglusib might
not only improve proliferation, but might also have a positive
effect on neurite pathology. We evaluated the effect of tideglusib
on SPG11 patients’ neurons. After confirming the presence
of neurite pathology in iPSC derived cortical neurons from
SPG11 patients and genome edited lines, we here established
a treatment regimen for differentiated cortical neurons. By
analyzing neuronal morphology and survival, we demonstrate
that tideglusib is capable to reduce these neuronal impairments.
MATERIALS AND METHODS
Patients
The patients included in this study (n = 3; Table 1) were female
Caucasians with genetically confirmed compound heterozygous
mutations in SPG11 (Hehr et al., 2007; Bauer et al., 2009; Pérez-
Brangulí et al., 2014). SPG11-1 and SPG11-2 are sisters with
a heterozygous nonsense mutation at c.3036C>A/p.Tyr1012X
in exon 16 and a c.5798delC/p.Ala1933ValfsX18 mutation in
exon 30. SPG11-3 has a heterozygous nonsense mutation at
c.267G>A/p.Trp89X in exon 2 and a splice site mutation 1457-
2A>G in intron 6. All patients were severely affected, also
indicated by high scores on the Spastic Paraplegia Rate Scale (33–
39 out of max. of 52; Schüle et al., 2006). All patients have a TCC
accompanied by cognitive impairment, white matter lesions,
cortical atrophy, as well as muscle wasting and motor-sensory
neuropathy (Hehr et al., 2007). The controls (CTRL1; CTRL2)
were age matched healthy Caucasian females with no previous
history of movement or neurological disorders.
iPSC Derivation
Fibroblasts from SPG11 patients and controls were
reprogrammed with retroviral transduction using the four
Yamanaka factors (Klf4, c-Myc, Oct4, and Sox2) as previously
described (Pérez-Brangulí et al., 2014). The Institutional
Review Board approval (Nr. 4120: Generierung von humanen
neuronalen Modellen bei neurodegenerativen Erkrankungen)
and informed and written consent forms are on file at the
Movement Disorder Clinic of the Department of Molecular
Neurology, Universitätsklinikum Erlangen (Erlangen, Germany).
All iPSC lines were screened for pluripotency and had a stable
karyotype using the G-banding chromosomal analysis (data
not shown). The SPG11 mutations were confirmed in the
patient-derived lines. Two iPSC lines were used for each patient
and control.
Targeted SPG11 Knock-Out With the
CRISPR/Cas9 System
To generate the SPG11 knock-out line (cSPG11) we targeted
exon 1 of SPG11 (Figure 4A). The single gRNAs (sgRNA)
(Sigma-Aldrich) were chosen with the CRISPOR web-tool1 and
cloned into the pX330 plasmid expressing SpCas9 (Addgene
plasmid #42230) and the sgRNA according to the guidelines
of the Zhang lab2. The cutting efficiency of the sgRNAs was
evaluated in transfected 293T cells, by T7 endonuclease-mediated
detection of insertions/deletions (indels) as previously described
(Turan et al., 2016). The highly efficient sgRNA with an off-
target score of 92 (sequence at Supplementary Figure S3)
was chosen for nucleofection of a human embryonic stem cell
line (hESC; HUES6). All the experiments with HUES6 were
conducted according to the German Stem Cell Act (RKI, 63.
Genehmigung to BW). Forty-eight hours after nucleofection,
cells were single cell sorted by flow cytometry, expanded and
validated for homozygous knock-out by T7-endonuclease assay
(Supplementary Figure S2A), sequencing (LGC genomics) and
TIDE genotyping analysis3. The positive clones and isogenic
control (clone that underwent the genome editing process
but had no mutations) were evaluated for exonic off-target
mutagenesis by PCR-mediated sequencing of potential off-
target sites of 5 candidate genes (selected with CRISPOR)
(Supplementary Figure S3A). The genome edited lines were
cultured on Matrigel (BD Biosciences) in mTeSR1 medium (Stem
Cell Technologies). Detailed experimental scheme appears in
Figure 4B.
Neuronal Differentiation and Tideglusib
Treatment
The generation of NPCs and subsequent differentiation from
pluripotent stem cells into neuronal cells was conducted
1http://crispor.tefor.net/
2https://www.addgene.org/crispr/zhang/
3https://tide.nki.nl/
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TABLE 1 | Clinical characterization of SPG11 patients and controls.
SPG11-1 SPG11-2 SPG11-3 CTRL-1 CTRL-2
SPG11 mutations Exon 16: c.3036C>A
Exon 30: c.5798delC
Exon 16: c.3036C>A
Exon 30: c.5798delC
Exon 2: c.267G>A
Intron 6:
c.1457-2A > G
− −
Sex Female Female Female Female Female
Age at onset/age at
examination (years)
24/46 20/40 31/50 –/45 –/28
SPRS (0–52) 44 37 36 0 0
Cognitive impairment + + + − −
Wheelchair dependency + + + − −
MRI abnormalities Cortical atrophy, WML,
TCC
Cortical atrophy, WML,
TCC
Cortical atrophy, WML,
TCC
− −
iPSC clones
(n = 2 per line)
SPG11-1a, SPG11-1b SPG11-2a, SPG11-2b SPG11-3a, SPG11-3b CTRL-1a, CTRL-1b CTRL-2a, CTRL-2b
Patients, SPG11-1, SPG11-2, SPG11-3; controls, CTR-1, CTRl-2; SPRS, spastic paraplegia rating scale; TCC, thin corpus callosum; WML, white matter lesion; iPSC,
induced pluripotent stem cells.
as described previously (Havlicek et al., 2014; Figure 1A).
Briefly, pluripotent stem cells were cultured with mTeSR1
medium (Stemcell Technologies) and passaged using Gentle Cell
Dissociation Reagent (Stemcell Technologies). For the generation
of free floating embryoid bodies (EBs), they were incubated for
45 min at 37◦C with Collagenase IV and transferred to ultra-
low attachment plates (Corning) for 1 week. Afterwards, the
EBs were transferred to polyornithine-laminin coated plates,
followed by manual collection of neural rosettes. Rosettes
were dissociated using TrypLETM Express and transferred to
proliferation media containing FGF2. For the induction of
neuronal differentiation, the cells were cultured in N2/B27 media
supplemented with the neurotrophins BDNF and GDNF, cAMP,
and ascorbic acid. Tideglusib (Selleckchem; diluted in DMSO)
was administered at the concentration of 1 µM to 1 week
differentiated neurons and was applied twice a week, during
media changes, for a period of 3 weeks (for details see paradigm
Supplementary Figure S1).
Immunofluorescence and Image Analysis
For stainings, 100,000 NPCs were plated on 24-well plates
with polyornithine-laminin coated glass cover slips and
treated according to the paradigm in Figure 1A. To quantify
neuronal cell death, PFA-fixed cells were pretreated with
acetic acid and ethanol at a 1:2 ratio at −20◦C for 5 min.
Afterward, the cells were stained with anti βIII-tubulin (Tuj-
1; 1:500; BioLegend) and anti-cleaved-caspase3 (cCasp3;
1:500; Cell Signaling Technology) antibodies and mounted
on microscope slides. Triplicate coverslips were used for
each cell line and three random images per coverslip with
comparable cell densities (40×) were acquired using Observer.Z1
fluorescence microscope (Zeiss). Representative images were
obtained with LSM-780 confocal microscope setups (Carl
Zeiss). For additional stainings, anti-glial fibrillary acidic
protein (1:500; DAKO), and anti-Ctip2 (1:300; Abcam)
antibodies were used. The quantifications were conducted
with the cell counter plugin of Fiji software (Schindelin et al.,
2012).
Gene Expression Analysis
The RNA was extracted using RNeasy kit (Qiagen) according
to the manufacturer’s instructions. A total of 500 ng RNA was
reverse-transcribed into cDNA in 20 µl reaction solution by
QuantiTect Reverse Transcription Kit (Qiagen). Subsequently,
1 µl of cDNA was used for real-time polymerase chain reaction
(qPCR). The qPCR program definitions were as follows: 95◦C for
10 min, followed by 40 cycles at 95◦C for 15 s and 60◦C for 1 min
and 1 cycle at 95◦C for 15 s, 60◦C for 30 s and 95◦C for 15 s. The
primers are listed in Supplementary Table S1.
Neurite Length and Complexity Analysis
Neurons derived from pluripotent stem cells were cultured in
24-well plates, on top of polyornithine-laminin coated glass
coverslips. In order to allow visualization of single neurons,
on day 26 the cells were transfected with pEF1-dTomato using
Lipofectamine, 2000 (Invitrogen, reagent:DNA ratio 2:1). The
cells were fixed 48 h after transfection with 4% paraformaldehyde
(PFA) in phosphate-buffered saline (PBS). The cells were stained
for neuronal marker expression using the anti-βIII-tubulin
antibody on coverslips (Tuj-1; 1:500; BioLegend), and the
coverslips were mounted on slides. Images were captured with
a 10× objective lens using the TILE function of the Zen Pro
Software (Zeiss) on the Observer.Z1 fluorescence microscope
(Zeiss). Semi-automated tracing of individual transfected βIII-
tubulin positive cells was performed using the NeuronJ plugin
of Fiji (Schindelin et al., 2012). A minimum of 36 cells per
patient/control and 18 cells for genome edited lines were
analyzed for the number of neurites and total neurite length.
Furthermore, semi-automated Sholl analysis was carried out
at predefined 50 µm intervals from the soma using the Fiji
software.
Electron Microscopy
Transmission electron microscopy was performed as described
previously (Schlotzer-Schrehardt et al., 2012; Havlicek et al.,
2014). Briefly, the neurons were fixed in 2.5% glutaraldehyde
in 0.1 M phosphate buffer. Subsequently, cells were post-fixed
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FIGURE 1 | Neuronal differentiation and characterization (A) Schematic representation of the differentiation of iPSCs into neuronal cultures. (B) Representative
images of CTRL (left; CTRL-1a) and SPG11 (right; SPG11-1b) 4 weeks differentiated neurons stained for GFAP and Tuj-1. (C) Quantification of percentage of
GFAP+/DAPI+ cells in CTRLs and SPG11. (D) qPCR data of 4 weeks differentiated neurons. RNA from four different iPSCs clones was used as negative control and
it is indicated as a dashed line at onefold change. (E) Representative images Ctip2 (red) and Tuj-1 (green) of CTRL and SPG11. Quantifications represent pooled
data of CTRLs (CTRL-1, CTRL-2) and SPG11 (SPG11-1, SPG11-2, SPG11-3) neurons. iPSCs, induced pluripotent stem cells; NPCs, neural progenitor cells. Scale
bar = 50 µm in (B) and 20 µm in (E). ∗P < 0.05.
in 2% buffered osmium tetroxide and dehydrated in graded
alcohol concentrations. Afterward, the cells were embedded
in epoxy resin. Horizontal sections were stained with uranyl
acetate and lead citrate. Finally, the sections were examined
using a transmission electron microscope (LEO 906E; Carl Zeiss
Microscopy).
Statistical Analysis
All statistical analyses were performed using IBM SPSS statistics
software (version 23). The Student two tailed t-test for unpaired
variables was applied when comparing the means between two
groups. For comparison of more than three groups, one-way
ANOVA followed by Bonferroni post hoc test was applied.
P-values ≤ 0.05 were considered statistically significant. Unless
indicated otherwise, all data are shown as mean± SEM.
RESULTS
Characterization of iPSC Derived
Neurons
The neuronal differentiation (described in Figure 1A) yields in
cortical neurons expressing a majority of Tuj-1 positive cells with
astrocytes comprising less than 10% of the cellular population
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(Figures 1B,C). There was no significant difference in the amount
of astrocytes between SPG11 lines and controls (Figure 1C).
Immunofluorescence stainings as well as qPCR analysis
confirm the neuronal cortical identity of the iPSC derived
cells (Figures 1D,E). Thus, both controls and SPG11 cell lines
exhibited a significantly higher transcript level of the deep
layer marker Ctip2 and the vesicular glutamate transporter 1
(VGLUT1) compared to iPSC lines (Figure 1D). The gene
expression levels did not differ between patients and controls
(Figure 1D).
Rescue of SPG11 Neurite Outgrowth
Abnormalities by Tideglusib Treatment
We first evaluated the neurite morphology of SPG11 iPSC derived
neuronal cultures and measured neuritic length and the number
of neurites per cell, indicative of neuritic complexity (Figure 2A).
Compared to CTRLs, neurite length was significantly decreased
by 78% in SPG11 (669.44 ± 50.34 µm in SPG11, compared to
3103.48 ± 328.04 µm in CTRL; P ≤ 0.05; Figure 2B). Moreover,
neurite number was significantly reduced (2.87± 0.16 in SPG11,
compared to 6.76 ± 1.0 in CTRL; P ≤ 0.05; Figure 2C). These
results are in agreement with the previously described neuritic
impairment in SPG11 iPSC derived neuronal cultures (Pérez-
Brangulí et al., 2014). We next tested the effect of the chronic
administration of 1 µM tideglusib. The rationale for this dose
was obtained from previous experiments, which revealed severe
toxicity at a higher dose (5 µM; data not shown). We applied the
compound twice a week for a period of 3 weeks until neurons
reach maturity (see paradigm Supplementary Figure S1).
Interestingly, chronic administration of tideglusib was able to
significantly rescue neurite length (2856.86 ± 151.65 µm in
SPG11 treated with tideglusib, compared to 3103.48± 328.04µm
in CTRL; P ≤ 0.05; Figure 2B). Moreover, neurite number was
restored to a level which was virtually comparable to CTRL
(6.48 ± 0.64 in SPG11 treated with tideglusib, compared to
6.76± 1.04 in CTRL; P ≤ 0.05; Figure 2C).
In order to further elaborate the effect of the chronic
administration of tideglusib on neurite complexity, Sholl analysis
was performed. The number of intersections of neurites at
various radial distances from the cell soma was measured and
revealed a significant increase in neuritic arborization of SPG11
patient derived neurons upon tideglusib treatment (Figure 2D).
This effect was significant for all distances’ measures (distances
from soma from 10 µm to 1660 µm, P ≤ 0.05).
Rescue of Neurodegeneration
Associated Characteristics in SPG11
iPSC-Derived Neurons by Tideglusib
Treatment
We next asked, whether treatment with tideglusib also has an
impact on neural cell death. We quantified the number of
cCasp3/Tuj1 double positive cells within the different groups
(Figure 3A). A significantly higher amount of neuronal cell death
was present in non-treated SPG11 neurons (23.34% ± 04.22%
cCas3+ cells in SPG11, compared to 14.17% ± 2.80% cCas3+
cells in CTRL; P ≤ 0.05; Figure 3C). In addition, the relative
survival rate was lower in SPG11 neurons compared to control
(0.87 ± 0.09 Tuj-1+/ cCas3− cells in SPG11 treated with
tideglusib, compared to 1.0± 0.09 Tuj-1+/cCas3− cells in CTRL;
P ≤ 0.05; Figures 3B,C). The treatment decreased the number
of cCas3+ cells to CTRL levels (15.68 ± 2.26% cCas3+ cells
in SPG11 treated with tideglusib, compared to 14.17 ± 2.80%
cCas3+ cells in CTRL; P ≤ 0.05; Figures 3A,C). Similarly, the
compound was also able to increase the survival rate of SPG11
neurons (0.96 ± 0.09 Tuj-1+/cCas3− cells in SPG11 treated
with tideglusib, compared to 1.0 ± 0.09 Tuj-1+/cCas3− cells
in CTRL; P ≤ 0.05; Figures 3B,C) to a level which did not
significantly differ from CTRL (P ≥ 0.05 according to Bonferroni
test; Figure 3D). We next sought to analyze the impact of
tideglusib on neurite ultrastructure.
The ultrastructural analysis of SPG11 iPSC derived 4-weeks
differentiated neurons revealed that the neurites accumulate
membrane-bound inclusion bodies measuring 0.3–1.5 µm in
diameter with electron-dense contents. Interestingly, tideglusib
treatment reverted this phenotype and led to an elimination of
these abnormal structures (Figure 3E).
CRISPR/Cas9 Mediated Generation and
Characterization of SPG11 Knock-Out
Line
Sequencing analysis of HUES6 line transfected with a plasmid
containing Cas9 and gRNA targeting exon 1 of SPG11 revealed
one clone with out-of-frame mutation (cSPG11, Figures 4C,D).
According to TIDE analysis, the clone was positive for out-of-
frame mutation in both alleles (Figures 4C,D). An additional
clone, that underwent the genome editing process, but had no
mutations (cCTRL; Figure 4D), was chosen as isogenic control.
Both cSPG11 and cCTRL were negative for off-target activity
(Supplementary Figures S3A,B). The reduction of spatacsin in
cSPG11 confirms the efficiency of the genome editing strategy
(Supplementary Figure S2B). The residual amount of the
protein can be attributed to the lack of specific and reliable
antibodies for spatacsin detection. Genome edited pluripotent
stem cells were differentiated according to the paradigm in
Figure 1A and were positive for Tuj1 (Figure 4E) with astrocytes
levels that, similarly to iPSC-derived neuronal cultures, were
lower than 10% and did not differ between cSPG11 and cCTRL
(Supplementary Figure S2C).
Rescue of Neurite Impairments in the Genome
Edited Line
Interestingly, the SPG11 genome edited line (cSPG11)
recapitulates the observations from the patients’ iPSC
derived neurons (Figures 4F,G). Thus, the neurites of
cSPG11 hES derived neuronal cultures are significantly
shorter (1115.99 ± 490.04 µm in cSPG11, compared to
2816.25 ± 948.44 µm in cCTRL; P ≤ 0.05; Figure 4F) and
fewer (3.22 ± 1.09 in cSPG11, compared to 5.66 ± 1.50
in cCTRL; P ≤ 0.05; Figure 4G) compared to isogenic
control (cCTRL). Similarly to the rescue of the patients’
lines, tideglusib administration rescued the neurite length
(3211.18 ± 1080.52 µm in cSPG11 treated with tideglusib,
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FIGURE 2 | Rescue of neurite outgrowth abnormalities of SPG11 patients by tideglusib treatment. (A) Representative image of non-treated (left) and tideglusib
treated (right) SPG11 neurons transfected with pEF1-dTomato. Neurite tracings are shown in the inserts. (B) The total neuritic length is significantly decreased in
SPG11 neurons and it is recovered following tideglusib treatment. (C) The average number of SPG11 neurites is significantly decreased and it is recovered following
tideglusib treatment. (D) Sholl analysis confirms a significant increase in neurite number following tideglusib treatment. Quantifications in C, D represent pooled data
of CTRLs (CTRL-1, CTRL-2) and SPG11 (SPG11-1, SPG11-2, SPG11-3) iPSC-derived-neurons. Scale bar = 100 µm. Data shown as means ± SEM. ∗P ≤ 0.05.
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FIGURE 3 | Neurodegeneration associated impairments in SPG11 neurons are rescued by tideglusib treatment. (A) Merged confocal images of SPG11 and CTRL
neurons generated from iPSCs and co-immunostained for βIII-tubulin (Tuj-1) and cleaved-caspase3 (cCasp3). Scale bar = 20 µm. (B) Representative images of
TUJ-1 stained SPG11 and control neurons. (C) Elevated cCasp3 levels in SPG11 neurons is rescued by tideglusib treatment. (D) Reduced level of Tuj-1 is rescued
by tideglusib treatment. (E) Ultrastructural analysis of the neurites of non-treated (left) and tideglusib treated (right) SPG11 4-week-differentiated-neurons reveals that
the membranous inclusion bodies (indicated by arrows) in SPG11 neurons are reduced in number and size following the treatment. Quantifications in (C,D) represent
pooled data of CTRLs (CTRL-1, CTRL-2) and SPG11 (SPG11-1, SPG11-2, SPG11-3) iPSC-derived-neurons. Scale bar = 20 µm in (A,B) and 1 µM in (E).
∗P < 0.05.
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FIGURE 4 | CRISPR/Cas9 genome edited hESC-derived-neurons recapitulate the neuritic phenotypes of patient iPSC-derived-neurons. (A) Strategy for SPG11
knock-out by targeting exon 1 of SPG11. (B) Experimental scheme for CRISPR/Cas9 mediated genome editing of hESCs. hESCs were nucleofected with 5 µg of
pX330 plasmid expressing SpCas9 and the sgRNA. After 48-h, the cells were single cell-sorted into 96-well plate. Subsequently, emerging colonies were split in 1:2
ratio. Half of the split was used for genomic DNA generation. The rest was transferred into a new 96-well plate for cryopreservation in –80◦C. For identification of
positive clones, PCR products were sequenced, further expanded and genotyped by Tracking Indels by Decomposition (TIDE; https://tide.nki.nl/) web-tool.
(C) Sequence comparison between reference non-nucleofected HUES6 cell line, a positive, genome edited clone (cSPG11) and a control that underwent the
genome editing process, but had no mutations (cCTRL). (D) TIDE analysis of cSPG11 and cCTRL. (E) Representative images of the genome edited lines stained for
Tuj-1 (green). (F) The total neuritic length is significantly decreased in cSPG11 neurons and it is recovered following tideglusib treatment. (G) The average number of
SPG11 neurites is significantly decreased and is recovered following tideglusib treatment. (H) Quantification of cCasp3+ cells reveals no significant difference
between cSPG11 and cCTRL. Data shown as means ± SD. Scale bar = 50 µm. ∗P < 0.05. FACS = Fluorescence-activated cell sorting.
compared to 2816.25 ± 948.44 µm in cCTRL; P ≤ 0.05;
Figure 4F) and complexity (5.33 ± 1.93 in cSPG11 treated
with tideglusib, compared to 5.66 ± 1.50 in cCTRL; P ≤ 0.05;
Figure 4G).
There was no evident change in the levels of cell death
between the genome edited control (cCTRL) and SPG11 knock-
out (cSPG11) lines (Figure 4H).
DISCUSSION
Our findings indicate a beneficial effect of tideglusib on
both cellular morphology and survival of SPG11-iPSCs-derived
neurons. This is the first indication of an effective therapeutic
approach applied to human SPG11 differentiated neurons.
First, our data confirm the findings from a previous
study (Pérez-Brangulí et al., 2014) that SPG11 neurons
present with impaired neuritic length and decreased
number of neurites, indicative of reduced neuronal
complexity. Our study was able to rescue these impairments
by administration of the irreversible GSK3 inhibitor,
tideglusib, to neuronal cells. In addition, we were able
to recapitulate virtually similar neuritic impairments,
followed by tideglusib rescue in CRISPR/Cas9 mediated
SPG11 knock-out line. Previous findings revealed that
SPG11 NPCs exhibit dysregulation of GSK3β/βCat
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signaling pathway (Mishra et al., 2016). The data of our
current study indicate that this pathway has a prominent
role not only during neural development, but also in
mature neurons. We are able to show, that in SPG11
tideglusib has a significant role in rescuing the neuritic
morphology.
Increased activity of GSK3β has been implicated in
neurodegeneration, particularly in Alzheimer’s Disease
(AD). Animal models overexpressing GSK3β exhibit one
of the main AD hallmarks – increased tau phosphorylation
(Brownlees et al., 1997; Lucas et al., 2001), whereas
overexpression of GSK3β in the dentate gyrus leads to
neurodegeneration of this area (de Barreda et al., 2010).
Tau hyper-phosphorylation, elevated amyloid levels and
activation of GSK3β are also present in AD-iPSC derived
neurons (Ochalek et al., 2017). Conversely, inhibition
of GSK3β leads to reduction of β-amyloid production
(Rockenstein et al., 2007) and its toxicity (Koh et al.,
2008), reduction of phosphorylated tau in cultured neurons
(Zhang et al., 2011) and improves learning and memory in
AD mouse models (Farr et al., 2016). Although the onset
and patterns of cognitive symptoms and cortical atrophy
present in SPG11 patients are markedly different from those
observed in AD patients, our data suggest that GSK3β over-
activation may be a common molecular denominator of both
diseases.
We next found that tideglusib treatment was able to rescue
the increased cell death of SPG11 neurons. The potential of
tideglusib to diminish apoptosis in SPG11 was first revealed in a
study where tideglusib administration to SPG11-NPCs improved
their survival and proliferation (Mishra et al., 2016). Here,
we extended the therapeutic value of tideglusib to neurons by
showing for the first time, that differentiating neurons are also
responsive to its effects. Our results are compatible with the
data indicating the important role of GSK3β in the regulation of
apoptosis (Jacobs et al., 2012). In addition, it has been shown that
GSK3β inhibition leads to neuroprotective effects (Culbert et al.,
2001).
Moreover, in rat cerebellar granule neurons cultures
GSK3β inhibition lead to increase of neuronal survival
(Song et al., 2010), whereas in a mouse model of CNS
injury it promoted axonal regeneration (Song et al.,
2010; Guo et al., 2016). Overall, these studies conclude
that GSK3β inhibition has a beneficial effect on mature
neurons which also provides an explanation to the
observed rescue of SPG11 neurodegenerative phenotypes
by tideglusib.
Interestingly, SPG11 knock-out line showed no difference
in cell death, and the number of cCas3 positive cells was not
changed following tideglusib treatment. This result may arise
from the vast heterogeneity and lack of correlation between
genotype and phenotype in SPG11. Thus, in addition to HSP
type 11, mutations in SPG11 can lead to autosomal recessive
juvenile amyotrophic lateral sclerosis and Charcot-Marie-Tooth
disease (Montecchiani et al., 2016). This observation indicates the
importance of the use of patient specific lines for disorders with
complex genotypes.
An additional important observation is that tideglusib
treatment leads to reduction of membranous inclusion bodies
in SPG11 neurites. The possibility to reduce this impairment
emphasizes the potency of tideglusib as a putative therapeutic
compound.
Overall, our results increase the clinical relevance of
the compound tideglusib and its potential to serve as a
therapeutic agent for SPG11. Furthermore, they contribute
to the establishment of iPSCs as a potent tool for disease
modeling and drug testing. The fact that tideglusib has
been approved by FDA and has been tested in clinical
trials of Alzheimer’s Disease, Autism Spectrum Disorder
and Myotonic Dystrophy renders a potential availability
also for SPG11 patients. Future studies that will utilize
the advanced cerebral organoid models and delve into the
mechanistic changes occurring after compound administration
are essential for providing a robust basis for clinical
implementation.
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